WithdrawnNot applicableNCT02006849
ACTH Treatment of APOL1- Associated Nephropathy
Studying REN-related autosomal dominant tubulointerstitial kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Mariana Murea, MDWake Forest University Health Sciences
- Intervention
- Acthar(drug)
- Eligibility
- 21 years · All sexes
- Timeline
- 2014 – 2019
Study locations (1)
- Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02006849 on ClinicalTrials.govOther trials for REN-related autosomal dominant tubulointerstitial kidney disease
Additional recruiting or active studies for the same condition.
See all trials for REN-related autosomal dominant tubulointerstitial kidney disease →